Doctor Erik Haakansson

Umea University Hospital, Umea (Sweden)

Follow

Contributor content

Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study

Presentation

Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study

ESC 365 is supported by

novartis

Explore sponsored resources